Leerink Partnrs Forecasts OmniAb’s Q4 Earnings (NASDAQ:OABI)

OmniAb, Inc. (NASDAQ:OABI) – Stock analysts at Leerink Partnrs lifted their Q4 2025 EPS estimates for shares of OmniAb in a report issued on Tuesday, November 4th. Leerink Partnrs analyst P. Souda now expects that the company will post earnings of ($0.09) per share for the quarter, up from their prior estimate of ($0.11). The consensus estimate for OmniAb’s current full-year earnings is ($0.61) per share. Leerink Partnrs also issued estimates for OmniAb’s Q1 2026 earnings at ($0.11) EPS, Q2 2026 earnings at ($0.12) EPS, Q3 2026 earnings at ($0.12) EPS, FY2026 earnings at ($0.46) EPS and FY2027 earnings at ($0.45) EPS.

OABI has been the subject of a number of other reports. Royal Bank Of Canada lowered their price target on shares of OmniAb from $4.00 to $3.00 and set an “outperform” rating for the company in a report on Thursday, August 7th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of OmniAb in a research note on Tuesday, October 14th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, OmniAb currently has a consensus rating of “Moderate Buy” and a consensus price target of $6.67.

OmniAb Price Performance

OABI opened at $1.38 on Friday. The stock’s 50 day simple moving average is $1.61 and its 200 day simple moving average is $1.70. The firm has a market cap of $198.66 million, a price-to-earnings ratio of -2.38 and a beta of 0.15. OmniAb has a 1 year low of $1.22 and a 1 year high of $4.71.

OmniAb (NASDAQ:OABI) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.01. The business had revenue of $2.24 million during the quarter, compared to analyst estimates of $5.64 million. OmniAb had a negative net margin of 301.83% and a negative return on equity of 23.14%. OmniAb has set its FY 2025 guidance at EPS.

Hedge Funds Weigh In On OmniAb

A number of institutional investors and hedge funds have recently added to or reduced their stakes in OABI. Kent Lake PR LLC lifted its position in shares of OmniAb by 677.8% during the second quarter. Kent Lake PR LLC now owns 1,750,000 shares of the company’s stock worth $3,045,000 after acquiring an additional 1,525,000 shares in the last quarter. Marshall Wace LLP bought a new position in OmniAb in the 2nd quarter valued at $626,000. Private Management Group Inc. grew its position in shares of OmniAb by 13.3% during the 1st quarter. Private Management Group Inc. now owns 2,529,759 shares of the company’s stock valued at $6,071,000 after purchasing an additional 296,711 shares in the last quarter. Towerview LLC raised its position in shares of OmniAb by 43.3% in the second quarter. Towerview LLC now owns 831,100 shares of the company’s stock worth $1,446,000 after buying an additional 251,100 shares in the last quarter. Finally, Ameriprise Financial Inc. boosted its stake in OmniAb by 854.6% during the second quarter. Ameriprise Financial Inc. now owns 279,789 shares of the company’s stock valued at $487,000 after buying an additional 250,479 shares during the period. Institutional investors own 72.08% of the company’s stock.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.